Articles From: Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride to Actavis Outlines Standalone Pharmaceutical Pipeline at Investor Meeting


2014/12/24
- Indicated for Treatment of Moderate to Severe Alzheimer's Disease - DUBLIN and EMERYVILLE, Calif., Dec.
Sign-up for Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride investment picks
2015/1/12
Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Actavis’ pending acquisition of Allergan.
Sign-up for Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis’ Pending Acquisition of Allergan and Record Dates for Shareholder Meetings investment picks
2015/1/6
- Potential Treatment of Both Schizophrenia and Manic or Mixed Episodes Associated with Bipolar I Disorder - DUBLIN and BUDAPEST, Hungary , Jan.
Sign-up for Actavis and Gedeon Richter Announce FDA Receipt of NDA Resubmission for Cariprazine investment picks
2015/2/27
- LILETTA™ Offers Women Broad Access to Safe, Effective Long-Term Contraception through Groundbreaking Company Partnership - DUBLIN and SAN FRANCISCO , Feb.
Sign-up for Actavis and Medicines360 Announce FDA Approval of LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years investment picks
2015/3/2
DUBLIN , March 2, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has closed its concurrent offerings of 14,513,889 Ordinary Shares at $288.00 per share and 5,060,000 5.500% Mandatory Convertible Preferred Shares, Series A, at $1,000.00 per share, each having been offered in a separate registered public offering.
Sign-up for Actavis Announces Closing of Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan investment picks
2015/1/12
- Earnings and Business Update Scheduled for February 18th - DUBLIN , Jan.
Sign-up for Actavis Announces Exceptional Preliminary Fourth Quarter 2014 Performance investment picks
2015/2/4
- Proposed label expansion would support use of TEFLARO in cases of acute bacterial skin and skin structure infections (ABSSSI) with concurrent bacteremia - DUBLIN , Feb.
Sign-up for Actavis Announces FDA Acceptance of sNDA to Expand TEFLARO® (ceftaroline fosamil) Labeling investment picks
2015/2/18
- Unites Global Brand Portfolio Under Allergan Name - - Retains Actavis Name for Select Geographic Regions and Product Portfolios- - Recognizes Heritage and Customer Equity of Both Names - - Company to Operate Under Unified Management Team, Single Vision and Culture - - Shareholder Approval Required - DUBLIN , Feb.
Sign-up for Actavis Announces Intention to Adopt "Allergan" Corporate Name investment picks
2015/3/3
DUBLIN , March 3, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has priced an offering of $21 billion aggregate principal amount of senior unsecured notes in 10 tranches in a registered public offering to be issued by its indirect wholly-owned subsidiary, Actavis Funding SCS, and guaranteed by certain of its other subsidiaries (the "Notes"), as follows: Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO Description Amount Maturity Price to Public Floating Rate Senior Notes* $500,000,000 Due 2016 100.00% 1.850% Senior Notes $1,000,000,000 Due 2017 99.954% 2.350% Senior Notes $3,000,000,000 Due 2018 99.951%
Sign-up for Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan investment picks
2015/3/2
DUBLIN , March 2, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it is commencing an offering of senior unsecured notes in multiple tranches in a registered public offering to be issued by its indirect subsidiary, Actavis Funding SCS, and guaranteed by certain of its other subsidiaries, subject to market and other conditions (the "Notes").  Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO Actavis plc intends to use the net proceeds from the offering of the Notes, together with the proceeds from its offerings of its Ordinary Shares and 5.500% Mandatory Convertible Preferred Shares, Series A (together with the offering of Ordinary Shares, the "Equity Offerings"), and additional debt financing, including borrowings under unsecured term loan facilities and an unsecured cash bridge loan facility, to finance the cash portion of the merger consideration for its previously announced
Sign-up for Actavis Announces Proposed Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan investment picks
2014/12/16
- Brent Saunders to Lead as CEO and President - - Leadership Reflects Exceptional Combined Expertise of Actavis and Allergan - - Commercial Leadership Operating Model to Optimize Allergan Expertise and Capitalize on Expanded Global Footprint - - Brand Research & Development to Report Directly to CEO - - Enhanced Linkage between Global Operations, Generic R&D and Generic Commercial Markets - DUBLIN , Dec.
Sign-up for Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition investment picks
2014/12/11
DUBLIN , Dec.
Sign-up for Actavis Confirms District Court Ruling to Require Continued Distribution of NAMENDA IR investment picks
2015/2/24
DUBLIN , Feb.
Sign-up for Actavis Confirms Generic Uceris® Patent Challenge investment picks
2015/2/17
DUBLIN , Feb.
Sign-up for Actavis Confirms Temporary Injunction From Appeals Court Related to Generic Pulmicort RESPULES® investment picks
2015/2/18
By Michael Calia Actavis PLC raised its profit guidance for 2015, while acquisitions again helped drive revenue growth in the fourth quarter, as the company awaits the close of its deal to buy Botox maker Allergan Inc. The results easily surpassed analysts' expectations.
Sign-up for Actavis Earnings Soar as Closing of Allergan Deal Looms investment picks
2015/2/18
By Michael Calia Actavis PLC on Wednesday said it plans to change its name to Allergan, the moniker of the Botox maker it has agreed to acquire.
Sign-up for Actavis Earnings Soar as Closing of Allergan Deal Looms -- Update investment picks
2015/1/12
By Michael Calia Pharmaceutical company's deal to buy Allergan clears U.S. antitrust wait Actavis PLC, which is in the process of acquiring of Botox maker Allergan Inc., said it expects its fourth-quarter results to top analysts' expectations, capping what Chief Executive Brent Saunders called an "exceptional year" for the company.
Sign-up for Actavis expects profit to beat expectations investment picks
2015/3/3
By Mike Cherney Actavis PLC launched a $21 billion bond sale Tuesday and lowered the expected yields on the deal, reflecting strong investor demand for a bond that should rank as the second-largest corporate offering on record.
Sign-up for Actavis Launches $21 Billion Bond Sale investment picks
2015/2/13
DUBLIN , Feb.
Sign-up for Actavis Launches Generic Pulmicort RESPULES® investment picks
2014/12/10
DUBLIN , Dec.
Sign-up for Actavis Launches Generic Version of Celebrex® investment picks
2015/1/13
- Products to be Marketed to Clinics and Hospitals across the United States - - Industry-Leading Pipeline in Development - DUBLIN , Jan.
Sign-up for Actavis Launches U.S. Generic Specialty Injectable Portfolio investment picks
2015/3/3
By Mike Cherney Actavis PLC lowered the expected yields on its more-than-$20 billion bond sale Tuesday, reflecting strong investor demand for a bond that should rank as the second-largest corporate offering on record.
Sign-up for Actavis Lowers Yields On Megabond Sale investment picks
2014/12/22
DUBLIN , Dec.
Sign-up for Actavis Names Jonathon Kellerman Executive Vice President, Global Chief Compliance Officer investment picks
2015/2/18
- Adjusted EBITDA Increases 80% to $1.5 Billion in Fourth Quarter 2014 - - $12.8 Billion Full Year Non-GAAP Net Revenue Increases 48% - - $4.5 Billion Full Year Adjusted EBITDA Increases 99% - - Exceptional Performance across Global Businesses - - GAAP Loss per Diluted Share in Fourth Quarter of $2.76 - - Standalone 2015 Forecast Raised to $16.30-$17.30 - DUBLIN , Feb.
Sign-up for Actavis Non-GAAP Net Revenue Increases 44% to $4 Billion in Fourth Quarter 2014; Non-GAAP EPS Increases 23% to $3.91; Increases 2015 Standalone Forecast investment picks
2015/2/18
- 9 mid- to late-stage compounds in development - - Novel compounds in specialty and primary care markets with high unmet medical need - - Industry-leading productivity across generic pipeline - - More than 40 ANDAs filed in 2014; 25 Confirmed First-to-Files - DUBLIN , Feb.
Sign-up for Actavis Outlines Standalone Pharmaceutical Pipeline at Investor Meeting investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride to Actavis Outlines Standalone Pharmaceutical Pipeline at Investor Meeting
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent